Physician profile
Vivek Radhakrishnan
NPI 1699271965
$1,076.28
in general payments reported to CMS, 2019-2025
16 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.43 · 2022: $51.12 · 2023: $108 · 2024: $425 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $325.70 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $128.32 | 2022-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $89.05 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $82.64 | 2024 | |
| Ardelyx, INC. | $76.90 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $60.67 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.68 | 2024-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $46.23 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $41.87 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $33.35 | 2025 | Voquezna |
| Abbvie INC. | $31.51 | 2024 | |
| Alexion Pharmaceuticals, INC. | $30.88 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $22.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.42 | 2023 | |
| Pfizer INC. | $18.94 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Radhakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.